moxisylyte has been researched along with Cavernitis, Fibrous in 2 studies
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Porst, H | 1 |
| Buvat, J | 1 |
| Buvat-Herbaut, M | 1 |
| Lemaire, A | 1 |
| Marcolin, G | 1 |
1 trial available for moxisylyte and Cavernitis, Fibrous
| Article | Year |
|---|---|
[Treatment of impotence with intracavernous auto-injections: moxisylyte diminishes the risks compared to papaverine].
Topics: Adult; Aged; Erectile Dysfunction; Humans; Injections; Male; Middle Aged; Moxisylyte; Papaverine; Pe | 1993 |
1 other study available for moxisylyte and Cavernitis, Fibrous
| Article | Year |
|---|---|
The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence.
Topics: Alprostadil; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Male; Molsidomine; Moxisylyte; P | 1995 |